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Background and Aims: In ulcerative colitis (UC), inflammation begins in the rectum and
can extend proximally throughout the entire colon. The extension of inflammation is an
important determinant of disease course, and may be limited by the action of regulatory
T cells (Tregs). In this cross-sectional study, we evaluated the relationship between UC
extension and the proportions of CD3+CD4+Foxp3+ and CD3+CD4+LAP+Foxp3-
Tregs in the colonic lamina propria (LP) of 79 UC patients and 29 controls. The role of
these cells in UC extension was also investigated in the murine oxazolone-induced colitis
model.
Methods: Patients: Disease extension was classified according to the Montreal
classification. Where possible, endoscopic biopsies of involved and uninvolved
tissue were obtained from UC patients. Mouse model: Colitis was induced by
intrarectal oxazolone administration. Lamina propria mononuclear cells were isolated
from patient biopsies and mouse colon tissue using enzymatic method and the
percentage of CD3+CD4+Foxp3+ and CD3+CD4+LAP+Foxp3-cells evaluated by
immunofluorescence. Confocal microscopy was applied for the visualization and
quantification of CD4+LAP+ cells on tissue histological sections.
Results: In UC patients with distal colitis the proportion of LP CD3+CD4+Foxp3+
Tregs was significantly higher in inflamed tissue than uninvolved tissue. As opposite, the
proportion of LP CD3+CD4+LAP+ Tregs was significantly higher in uninvolved tissue
than involved tissue. Both LP CD3+CD4+Foxp3+ and LP CD3+CD4+LAP+ Tregs
proportion in involved tissue was significantly higher than in controls irrespective of the
extension of inflammation. In mice with oxazolone-induced distal colitis, treatment with
LAP-depleting antibody was associated with the development of extensive colitis.
Conclusions: Our findings suggest that CD3+CD4+LAP+Foxp3-Tregs limit the
extension of inflammatory lesions in UC patients.
Keywords: CD3+CD4+LAP+Foxp3-regulatory cells, inflammation, immunity, oxazolone colitis, regulatory T cells,
ulcerative colitis
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INTRODUCTION
Ulcerative colitis (UC) is characterized by inflammation,
typically restricted to the mucosal surface that begins in the
rectum and can continuously extend proximally throughout the
entire colon (1). A prospective study of Norwegian UC patients
found that at the time of presentation, colitis was limited to the
rectum (proctitis) in one third of patients, the colorectum distal
to the splenic flexure (left-sided colitis) in another third, and
the area proximal to the splenic flexure (extensive colitis) in the
remaining third (2). In patients with distal colitis, inflammation
progresses in 25–50% of patients, while regression is observed in
about 16% of patients (3, 4). The anatomical extent of mucosal
inflammation is one of the most important factors determining
disease course. Patients with extensive colitis have a greater
risk of colectomy than those with proctitis (5–7), as well as a
greater risk of colorectal cancer (8, 9). Proximal disease extension
is associated with increased disease severity upon diagnosis
and greater likelihood of clinical relapse (10, 11). Moreover,
extensive colitis is associated with an increased frequency
of extraintestinal manifestations, a steroid-refractory disease
course, and the need for immunosuppressive and immune-
modulating medications and surgery (10, 12). Younger age at
diagnosis and the presence of sclerosing cholangitis are pre-
existing independent predictive factors for disease progression
(12).
The biological factors that determine the extent of
inflammation in UC are unknown. Tregs have been identified
as a key immunosuppressive population that is critically
involved in maintaining intestinal homeostasis. Therefore,
we hypothesized that Tregs may be involved in limiting the
extension of inflammation. To investigate this hypothesis, we
evaluated the frequencies of different Treg types in the lamina
propria (LP) of UC patients with varying degrees of disease
extension, and examined the contribution of these cells to
disease extension in a mouse model of UC. Specifically, we
analyzed the frequencies of CD3+CD4+Foxp3+ cells, as well
as another type of Treg, CD3+CD4+ latency associated peptide
(LAP)+ Foxp3-regulatory cells. We previously demonstrated
that the latter cell type is present in human LP (13), and is found
at a higher frequency in the LP of endoscopically active UC
patients, but not in Crohn’s disease patients (14). Moreover,
LAP+ Foxp3− T cells have been described to infiltrate colorectal
cancer exhibiting more potent immunosuppressive activity than
Foxp3+ regulatory T cells (15).
We found that in UC patients with proctitis and left-
sided colitis the proportion of LP CD3+CD4+Foxp3+ Tregs
was significantly higher in inflamed tissue than uninvolved
tissue. As opposite, the proportion of LP CD3+CD4+LAP+
Tregs was significantly higher in uninvolved tissue than
involved tissue. In a mouse model of distal colitis (16), we
found that administration of an LAP-depleting antibody
that has no effect on the frequency of CD4+Foxp3+ Tregs
(17) was associated with the development of extensive
colitis, suggesting that CD3+CD4+LAP+Foxp3-regulatory
cells limit the extension of inflammatory lesions in
UC.
MATERIALS AND METHODS
Patients
A total of 95 patients with endoscopically active UC who
underwent colonoscopy for clinical flare-up at 2 tertiary
centers (IBD, GE Unit, Sandro Pertini Hospital, Rome, and
the Department of General Surgery, “P. Stefanini,” Sapienza
University, Rome) were included in the study. Disease activity
was assessed using the endoscopic Mayo score (18). Patients
with an endoscopic score ≥1, not on rectal 5-ASA and/or
steroids in the last 3 months, were considered to have
endoscopically active UC and were enrolled in the study. The
control group consisted of 29 participants [14 men, 15 women;
mean ± SE age, 55 ± 3 years; median (range) age, 56 (26–
85)] undergoing colonoscopy for colonic cancer screening and
suspected functional bowel disorders. In UC patients, disease
extension, at time of endoscopy, was classified using the
Montreal classification (19) as follows: proctitis, involvement
limited to the rectum; left-sided colitis, involvement limited
to a portion of the colorectum distal to the splenic flexure;
extensive colitis, involvement extending proximal to the splenic
flexure.
Biopsy Specimens
Multiple endoscopic mucosal biopsies were obtained. Biopsies
were taken from endoscopically involved and uninvolved areas
in UC patients, and from matched areas in controls. Diagnosis
of UC was established based on established criteria and the
localization and extension of the disease were confirmed by
histology. Histopathology was quantified in H&E stained tissue
sections using the Robarts histopathology index (RHI) (20). An
RHI≤6 in samples collected from involved tissue was considered
indicative of remission, and the sample, together with the paired
sample collected from uninvolved tissue, was excluded from the
analysis. Accordingly, 16 patients with a Mayo endoscopic score
= 1 were excluded from the analysis. The remaining 79 patients
were evaluated applying the aforementioned criteria. In these
patients, RHI < 3 were recorded for all biopsy samples collected
from uninvolved tissue. Histology confirmed the absence of
inflammatory changes in controls.
Some tissue sections were also analyzed by confocal
microscopy. Three micrometer thick paraffin-embedded sections
of human colon tissue from controls (CTR) and ulcerative
colitis (UC) patients were stained after deparaffinization in
xylene (5min, two times), rehydratation by sequential washes
in 100% ethanol (3min), 95% ethanol (3min), 80% ethanol
(3min), 70% ethanol, 50% ethanol, deionized water and antigen
retrieval (5min at 95◦C in 10mM sodium citrate, pH 6.0). Slides
were saturated with blocking buffer (PBS, 0.05% tween 20, 4%
BSA) for 1 h at room temperature. Specimens were stained with
a polyclonal rabbit anti-human CD4 at 5µg/ml, followed by
donkey anti-rabbit-AlexaFluor-568, and a monoclonal mouse
anti-human LAP followed by an goat anti-mouse AlexaFluor-
647. After washing, slides were mounted in Prolong Gold anti-
fade medium containing a DNA dye (DAPI). Confocal laser
scanning microscopy (CLSM) observations were performed with
a Leica TCS SP2 AOBS apparatus, using a 63x/1.40 NA oil
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objective. Acquisition of images was performed by a Leica
confocal software 2.6 (Leica, Germany).
Clinicopathological variables for all patients are shown in
Table 1.
Isolation of Lamina Propria Mononuclear
Cells (LPMCs)
LPMCs were isolated from freshly obtained biopsies using a
previously described DDT-EDTA collagenase method (13, 14).
Briefly, biopsies were washed in HBBS free of calcium and
magnesium (HBSS-CMF; Hyclone, Europe LTD, Cramlington,
United Kingdom), and then incubated for 5min at room
temperature in HBSS-CMF containing 1 mmol/l DTT (Sigma
Chemical Co., St. Louis, MO, United States) and antibiotics
(penicillin, 100 U/ml; streptomycin, 100 mg/ml; gentamicin,
50 mg/ml; and fungizone, 25 mg/ml). After washing 3 times
in HBSS-CMF, the biopsies were cut into smaller pieces and
incubated in HBSS-CMF containing 0.75 mmol/l EDTA, 10
mmol/l HEPES buffer, and antibiotics for 15min at 37◦C in a
humid 5% CO2 atmosphere to remove epithelial cells. After 2
washes, the tissue was incubated for a total of 2 h (2 × 1-h
incubations) at 37◦C in a humid 5%CO2 atmosphere in complete
medium (RPMI 1640 plus 10mM HEPES buffer, 2mM l-
glutamine, 10% heat-inactivated FCS (Hyclone), and antibiotics)
containing 25 U/ml collagenase V (Sigma-Aldrich, Milan,
Italy) and 100µg/ml of DNase (Roche Diagnostics, Mannheim,
Germany). After incubation, the supernatant containing LMPCs
was collected and washed twice in HBSS-CMF+ antibiotics.
Antibodies And Reagents
APC-Cy7-labeled anti-CD3, PE-Cy7-labeled anti-IL-10, and
isotype-matched control Igs were obtained from Biolegend (San
Diego, CA, United States). PE-labeled anti IL-17A, and isotype-
matched Ig control were obtained from eBioscience [San Diego,
CA, United States]. FITC-labeled anti-CD4, PE-CF594-labeled
anti-CD8 and isotype-matched control Ig were obtained from
Becton Dickinson Horizon (San Jose, CA, United States). PerCP-
labeled anti-LAP [TGF-β1] and isotype-matched control Ig were
obtained from R&D Systems (Minneapolis, MN, United States).
APC-labeled anti-Foxp3, the Foxp3 staining buffer set, and
isotype-matched control Ig were obtained from eBioscience (San
Diego, CA, United States). LIVE/DEAD R© Fixable Aqua Dead
Cell Stain Kit was obtained from Life Technologies (Carlsbad,
CA, United States). Phorbol-12-myristateacetate (PMA) and
ionomycin were obtained from Sigma-Aldrich. FITC-labeled
anti-CD4, isotype-matched control Igs, and Monensin solution
(Golgi Stop) were obtained from BD Pharmingen (San Jose,
CA, United States). For confocal microscopy imaging, polyclonal
rabbit anti-CD4 (Novus, Colorado, United States), Donkey anti-
rabbit-AlexaFluor-568 (Abcam, Cambridge, United Kingdom),
monoclonal mouse anti-human LAP (R&D Systems) and goat
anti-mouse AlexaFluor-647 (Abcam) were used.
Immunofluorescence Staining
Isolated LPMCs were incubated for 30min with LIVE/DEAD R©
Fixable Aqua Dead Cell Stain. Next, cells were washed and
stained with anti-human-CD3, anti-human-CD4, and anti-
human LAP (TGF-β1). After incubation, cells were washed,
fixed, and permeabilized with fixation/permeabilization solution
for 40min, and stained with anti-human Foxp3. In previous
studies (14), we established that the percentages of LAP+ and
Foxp3+ cells remained unchanged following PMA-ionomycin
stimulation in the presence of Golgi Stop. Therefore, for
evaluation of LAP and Foxp3 expression, together with that
of the intracellular cytokine IL-10 and IL-17, LPMCs isolated
from biopsies were incubated in X-VIVO15 medium and
stimulated for 4 hwith PMA (50 ng/ml) and ionomycin (1µg/ml)
in the presence of monensin (0.66 µl/ml Golgi Stop). After
stimulation, cells were recovered and washed in PBS-1X,
incubated for 30min with LIVE/DEAD R© Fixable Aqua Dead
Cell Stain, and washed and labeled. Given the downregulation
of CD4 expression that occurs following PMA-ionomycin
stimulation, CD8 staining was preferred. Consequently, to assess
TABLE 1 | Patient clinicopathological variables.
Disease
extension (n)
Age (years) mean ±
SE median (range)
Sex M/F
(n)/(n)
Disease duration
since diagnosis
(years) mean ± SE
median (range)
Mayo endoscopic
score mean ± SE
median (range)
Therapy
CS 5-ASA
agents
Immuno-
modulators
Biological
agents
Proctitis (21) 49 ± 3 52 (20–76) 17/14 10 ± 2 7 (0–35) 2 ± 0.1
2
(1–3)
5*+1 24 1 1
Left-sided Colitis
(22)
53 ± 3 54 (23–82) 21/11 12 ± 2 12 (0–37) 2 ± 0.1
2
(1–3)
4* 22 6*
Extensive Colitis
(16)
43 ± 5 46 (19–70) 9/7 10 ± 2 15 (0–24) 2 ± 0.2
2
(1–3)
2*+1 10 1*+1 1*+1
*Patients with combined therapy.
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FIGURE 1 | The frequency of LP CD3+CD4+LAP+ cells is higher in uninvolved (Uninv) vs. involved (Inv) colon tissue from UC patients. (A) Frequency of LP Foxp3+
cells in the CD3+CD4+-gated LPMC population: *P < 0.05 (Mann-Whitney U-test) for controls (Ctrl) vs. proctitis (Uninv + Inv), left-sided colitis (Inv), and extensive
colitis; **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue in proctitis and left-sided colitis. Data represent the mean ± SE of 79 UC patients and
29 controls. (B) Frequency of LP LAP+ cells in the CD3+CD4+-gated LPMC population: *P < 0.05 for Ctrl vs. proctitis (Uninv + Inv) and left-sided colitis (Inv); *P <
0.05 (Mann-Whitney U-test) for controls vs. left-sided colitis (Uninv + Inv) and extensive colitis; **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue
in proctitis and left-sided colitis. Data represent the mean ± SE of 79 UC patients and 29 controls. (C) Representative density plots of Foxp3 and LAP expression in
LP CD3+CD4+-gated cells. (D) Representative CD4+LAP+ T cells in colonic mucosa tissue of UC patients and controls. Confocal microscopy images of CD4
(green), LAP (red) and nuclei (blue) of matched involved and uninvolved colonic mucosa of a patient with UC, and a control subject (original magnification 630x).
CD4+LAP+ double positive T cells are indicated by white arrows. For UC, 1 representative staining of 4 patients is shown. For control subjects, 1 representative
staining of 2 subjects is shown. H&E stained sections of the corresponding subjects are also illustrated (original magnification 200x). (E) % of CD4+LAP+ cells in UC
patients (involved and uninvolved tissue) and controls. For quantification at least 3 images for each patient (n = 4) or control subjects (n = 2) were assessed. Data
represent mean ± SE, *P < 0.05 (Mann-Whitney U-test) for controls vs. uninvolved tissue; **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue.
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FIGURE 2 | Ratio between IL-10 and IL-17 expressing CD3+CD8-(CD4)LAP+ cells is significantly higher in uninvolved (Uninv) vs. involved (Inv) colon tissue from
ulcerative colitis patients. (A) Frequency of LP LAP+ cells expressing intracellular IL-17 *P < 0.05 (Mann-Whitney U-test) for controls vs. Involved (Inv) tissue in
proctitis, left sided colitis and extensive colitis. **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue in both proctitis and left-sided colitis. (B)
Frequency of LP LAP+ cells expressing intracellular IL-10: *P < 0.05 (Mann-Whitney U-test) for controls vs. proctitis (Uninv), left-sided colitis (Uninv + Inv), and
extensive colitis; **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue in both proctitis and left-sided colitis. (C) % LP LAP+ cells expressing
intracellular IL-10 / % LP LAP+ cells expressing intracellular IL-17 (ratio). **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue in proctitis, and left
sided colitis. *P < 0.05 (Mann-Whitney U-test) proctitis and left-sided colitis univolved tissue vs. controls * P < 0.05 (Mann-Whitney U-test) Extensive colitis vs.
proctitis and vs. left-sided colitis involved tissue. Data represent mean ± SE of 43 UC patients (proctitis, 16; left-sided colitis, 17; extensive colitis, 10) and 26 controls.
intracellular cytokine expression, cells were stained with anti-
human CD3, anti-human CD8, and anti-human LAP (TGF-β1),
and incubated for 30min. After incubation, cells were washed,
fixed, and permeabilized with fixation/permeabilization solution
for 40min. Cells were then washed in permeabilization buffer
and incubated for 30min with intracellular anti-human IL-10,
anti-human IL-17 and anti-human Foxp3 or isotype-matched
control Ig. Next, cells were washed twice with permeabilization
buffer solution and fixed with 2% paraformaldehyde. CD4
cells were defined as those with a CD3+CD8-signature. The
percentage of viable fluorescent cells was quantified using
a GalliosTM Flow Cytometer (Beckman Coulter, Brea, CA,
United States).
Induction of Experimental Colitis in Mice
Male BALB/c mice (Charles River Laboratories Italia, Calco,
Italy) were housed in the Allevamenti Plaisant (Rome, Italy)
animal facility in individually ventilated cages (IVC system)
containing enrichment devices. Maintenance of pathogen-free
conditions was ensured by monitoring every 6 months, in
accordance with the Federation of European Laboratory Animal
Science Associations (FELASA) recommendations. Experimental
colitis was induced in 6–7 week-old male BALB/c mice
by administering 6mg of oxazolone [(4-ethoxymethylene-
2-phenyl-2-oxazolin-5-one) Sigma Chemical Co., St. Louis,
MO, United States] dissolved in 50% ethanol (total injection
volume,150 µl), via a 3.5-F catheter inserted into the rectum of
lightly anesthetized mice, as previously described (15). Control
groups consisted of untreated mice and mice treated with
50% ethanol (total injection volume, 150 µl). Body weight was
recorded at time zero (moment of intrarectal oxazolone/ethanol
or ethanol administration), and on days 1 and 2 post-treatment.
Mice were sacrificed on day 2 by cervical dislocation and colons
collected for further analysis. In a preliminary experiment, we
tested the ability of anti-LAP antibody (TW7-16B4 antibody,
kindly donated by Professor HL Weiner, Harvard Medical
School, Boston, MA, USA) to deplete the LP CD4+LAP+cells.
To this end we treated two different groups of mice for 5
days with daily injection (40 µg, i.p.) of anti-LAP antibody or
isotype control mouse IgG1 Clone MOPC-21 (BioXCell; DBA,
Segrate, MI). Mice were sacrificed, colons were collected, and
isolated LPMC cells were analyzed by immunofluorescence for
LAP and Foxp3 expression. In additional experiments, different
groups of mice received daily injections (40 µg, i.p.) of anti-LAP
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FIGURE 3 | Reduced disease extension is associated with a higher percentage of CD3+CD8-(CD4) LAP+ cells in uninvolved vs. involved colon tissue from UC
patients. (A) Frequency of LP LAP+ cells in CD3+CD8- (CD4)-gated cells: *P < 0.05 (Mann-Whitney U-test) for controls vs. uninvolved tissue in proctitis + left-sided
colitis; **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue in proctitis + left-sided colitis. (B) Frequency of LP LAP+ cells expressing intracellular
IL-10: **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue in proctitis + left-sided colitis. (C) Frequency of LP Foxp3+ cells in CD3+CD8-
(CD4+)-gated cells: **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue in proctitis + left-sided colitis. In all cases, data represent the mean ± SE
of 26 controls and of 13 UC patients with a history of extensive colitis in whom inflammatory lesions were limited to the rectum or left colon at the moment of
endoscopy. Patient clinicopathological variables of this UC subgroup are not different from the whole UC patients population [Age: 53 ± 3–53 (29–73) (years) mean ±
SE-median (range); Sex: 7/6 M/F; Disease duration since diagnosis:14 ± 3.2–12 (1–32); (years) mean ± SE-median (range). Mayo endoscopic score: 2 ± 0.2–2 (1–3)
mean ± SE-median (range)].
antibody (or isotype control), for 5 days before the induction of
colitis.
Assessment of Colitis
Collected colons were macroscopically examined to assess the
extension of colitis, and histological analysis of colitis was
performed in colonic tissue samples that were fixed in 10%
neutral buffered formalin solution (Sigma-Aldrich), embedded in
paraffin, cut into tissue sections, and stained with hematoxylin
and eosin. Multiple serial sections dividing the colon into
three sections (proximal, medial and distal) were performed.
Stained sections were examined by a pathologist [ISTOVET
di Luca Crippa and C. S.A.S., Besana in Brianza (MB),
Italy] and the extension of inflammatory lesions determined.
Histopathologic grading of oxazolone-induced colitis was
performed as previously described (23). Briefly, 5 criteria
(hypervascularization, presence of mononuclear cells, epithelial
hyperplasia, epithelial damage, presence of granulocytes and
mucosal hemorrhages) were scored from 0 to 3 to produce a
cumulative histopathologic score (HS) ranging from 0 (no colitis)
to 15 (maximal colitis activity).
LPMCs Immunofluorescence Staining
Freshly isolated and washed LPMCs were subjected to Fc block
with anti-CD16/CD32 (BD Pharmingen) and then labeled for
30min with LIVE/DEAD R© Fixable Aqua Dead Cell Stain. After
washing, cells were stained by incubation for 30min with
APC-Cy7-labeled anti-CD3 (eBioscience), V450-labeled anti-
CD4 (eBioscience), PE-labeled anti-LAP (BioLegend), or isotype
control PE-labeled mouse IgG1 (R&D Systems). Intracellular
Foxp3 expression was evaluated using the APC-anti-mouse/rat
Foxp3 staining kit (eBioscience), following the manufacturer’s
protocol. The cells were then washed twice, and the percentage
of fluorescent cells quantified using a GalliosTM Flow Cytometer
(Beckman Coulter, Brea, CA, United States).
Some tissue sections were also analyzed by confocal
microscopy, using the above-described procedure. Briefly,
3 µm-thick paraffin-embedded sections of unlesional and
lesional colon tissues from mice treated as described in
Induction of experimental colitis in mice paragraph were
stained after deparaffinization, rehydratation, antigen retrieval
and saturation with blocking buffer. Specimens were stained
with a monoclonal FITC-conjugated rat anti-mouse CD4 at
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5µg/ml (BD Biosciences), and a monoclonal mouse anti-mouse
LAP at 5µg/ml (BioLegend) followed by an goat anti-mouse
AlexaFluor-633. After washing, slides were mounted in Prolong
Gold anti-fade medium containing a DNA dye (DAPI). Confocal
laser scanning microscopy (CLSM) observations were performed
with a Leica TCS SP2 AOBS apparatus, using a 63x/1.40 NA
oil objective. Acquisition of images was performed by a Leica
confocal software 2.6 (Leica, Germany).
Statistical Analysis
Data were analyzed using the two sided Mann-Whitney U-test
and the two sided Wilcoxon signed-rank test in GraphPad Prism
software (GraphPad Software, San Diego, CA, United States).
Statistical significance was set at p < 0.05.
Human Study
All participants provided written informed consent prior to
inclusion in the study. Ethical approval was provided by the
Ethical Committee of the Istituto Superiore di Sanità (Reference:
Pre-C-871/14, 25/11/2014).
Animal Studies
This study was carried out in accordance with the
recommendations of Decreto Legislativo 4 marzo 2014, n. 26
according with 2010/63/UE(14G00036) direction. The protocol
was approved by the Italian Ministry of Health (Reference:
16/2014-PR [DGSAF 12073-A, 05/06/2014], 03/10/2014).
RESULTS
The Frequency of LP CD3+CD4+LAP+
Cells Is Higher in Uninvolved vs. Involved
Colon Tissue From Ulcerative Colitis
Patients
Preliminary analyses of the percentage of CD3+CD4+LAP+
and CD3+CD4+Foxp3+ Tregs isolated from biopsies from
different portions of control colons revealed no differences
between colon regions (Supplementary Figure 1). We
next evaluated the frequency of LP CD3+CD4+LAP+ and
CD3+CD4+Foxp3+ Tregs in LPMCs isolated from biopsies
from controls and from patients with endoscopically and
histologically active UC with varying degrees of disease
extension. In patients with either proctitis or left-sided colitis,
the percentage of CD4+Foxp3+ cells was significantly higher
in involved tissue than in uninvolved tissue (Figure 1A). As
opposite % of CD4+LAP+ T regs was significantly higher in
uninvolved vs. involved tissue (Figure 1B) In agreement with
previous observations (14, 24, 25), the percentage of Foxp3+
Tregs in the LP CD3+CD4+ T-cell population was significantly
higher in involved tissue, regardless of disease extension, than
in controls (Figure 1A). Similarly, in line with previous reports
(14), the percentage of CD4+LAP+ Tregs was significantly
higher in involved tissue from patients with extensive colitis and
left-sided colitis than in controls (Figure 1B). In uninvolved
tissue, the percentage of CD4+Foxp3+ cells was comparable
to that of controls, while the percentage of CD4+LAP+ Tregs
tissue was significantly higher. As previously reported (14),
the majority of LAP+ cells detected were Foxp3- (Figure 1C).
Some biopsy specimens sections were also immunofluorescence
stained for tissue assessment of CD4+LAP+ cells by confocal
microscopy. As illustrated in Figures 1D,E, uninvolved tissue
showed significantly more CD4+LAP+ double-fluorescent cells
when compared with involved and control tissue.
Ratio Between IL-10 and IL-17 Expressing
LAP+ Cells Is Significantly Higher in
Uninvolved vs. Involved Colon Tissue From
Ulcerative Colitis Patients
We have previously shown that in active UC patients, LP
CD3+CD8- (CD4) LAP+ cells are enriched for IL-17 expression,
showing reduced suppressor activity due the intracellular IL-17
expression (14). It has been recently reported that CD4+LAP+
cells expressing IL-10 exhibit regulatory activity (26, 27). We
therefore evaluated IL-17 and IL-10 expression in LP CD3+CD8-
(CD4) LAP+ cells. As shown in Figure 2A, the percentage of IL-
17 expressing LP CD3+CD8- (CD4) LAP+ cells was significantly
reduced in uninvolved vs. involved tissue while the % of IL-10-
expressing LAP+ cells was significantly higher in uninvolved
vs. involved tissue (Figure 2B). As a consequence, the ratio
between IL-10 and IL-17 expressing LAP+ cells was significantly
higher in uninvolved vs. involved tissue (Figure 2C). Notably,
extensive colitis ratio was significantly lower than the ratio
observed both in proctitis and left-sided colitis involved tissue. As
previously reported and confirmed in the present study, % of IL-
17 expressing LAP+ cells was significantly increased in involved
tissues vs. controls (14). % of IL-10 expressing LAP+ cells was
significantly increased in uninvolved tissues vs. controls.
Reduced Disease Extension Is Associated
With a Higher Percentage of CD3+CD8–
(CD4+) LAP+ Cells in Uninvolved vs.
Involved Tissue From Ulcerative Colitis
Patients
To determine whether the observed differences in Tregs
frequencies were indeed linked to the extension of inflammatory
lesions, we analyzed a subgroup of patients with a history of
endoscopic assessed extensive colitis in whom inflammatory
lesions were endoscopically limited to the distal colon (mainly
rectum) at the moment of the entry in the present study.
We found that the presence of distal inflammatory lesions
was associated with a significantly higher frequency of LAP+
cells in LP cells isolated from uninvolved tissue vs. both
control tissue and involved tissue from UC patients (Figure 3A).
Within this cell population, the percentage of IL-10-expressing
CD4+LAP+ cells was significantly higher in uninvolved vs.
involved tissue (Figure 3B). The percentage of CD4+Foxp3+
Tregs was significantly higher in involved vs. uninvolved tissue,
in which values were comparable to those detected in controls
(Figure 3C). These findings suggest that the differences in the
frequencies of regulatory cells between involved and uninvolved
tissue are linked to the extension of inflammatory lesions.
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FIGURE 4 | Oxazolone-induced colitis reproduces the observations made in UC patients. (A) Weight changes in mice after intrarectal administration of oxazolone (6
mg/ethanol 50%). Each point represents the cumulative mean (± SE) weight from 3 separate experiments in which 5 mice per group were studied. *P < 0.05
(Student’s t-test) for EtOH 50% vs. OXZ 6 mg/EtOH 50%. (B) Representative macroscopic (on the left) and corresponding microscopic (on the right) images of the
colons from untreated (a), EtOH 50%-treated (b), and OXZ 6mg /EtOH 50%-treated (c) mice, all of which were sacrificed 2 days post-treatment. H&E staining of distal
(untreated), distal and medial colonic tract of EtOH 50%-treated and oxazolone-treated miceat 40× magnification. HS, histopathologic score (see methods). (C)
Percentage of LAP+ cells among CD3+CD4+-gated LMPCs isolated from the colon of untreated, ethanol-treated and oxazolone/ethanol-treated mice: *P < 0.05 for
untreated mice vs. OXZ-treated mice (uninvolved tissue); **P < 0.05 for uninvolved vs. involved tissue in OXZ-treated mice. Each point represents mean ± SE of
pooled values derived from 3 experiments in which 5 mice per group were evaluated. (D) Percentage of Foxp3+ cells among CD3+CD4+-gated LMPCs isolated
from the colon of untreated, ethanol-treated, and oxazolone/ethanol-treated mice: *P < 0.05 (Mann-Whitney U-test) for untreated mice vs. OXZ-treated mice (involved
tissue); **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue in OXZ-treated mice. Each point represents the mean ± SE of pooled values derived
from 3 experiments in which 5 mice/group were evaluated. (E) Representative CD4+LAP+ T cells in colonic mucosa of involved and uninvolved tissue of
oxazolone-treated mice. Confocal microscopy images of CD4 (green), LAP (red) and nuclei (blue) of matched involved and uninvolved colonic mucosa of a
oxazolone-treated mouse (original magnification 630x). CD4+LAP+ double positive T cells are indicated by white arrows. 1 representative staining of 3 mice is shown.
H&E stained sections of the corresponding confocal images are also illustrated (original magnification 40x). The rectangles highlight the area shown in the confocal
microscopy images. (F) % of CD4+LAP+ cells in colons of oxazolone-treated mice (involved and uninvolved tissue). For quantification at least 3 images for each
colon (n = 3) were assessed. Data represent mean ± SE, **P < 0.05 (Wilcoxon signed-rank test) for uninvolved vs. involved tissue.
Depletion of LAP+ Cells Is Associated With
Proximal Extension of Inflammatory
Lesions in the Murine Oxazolone-Induced
Colitis Model
To gain further insight into the roles of the two aforementioned
Tregs subsets in limiting the extension of inflammatory lesions,
we evaluated the effect of in vivo administration of an
LAP-depleting antibody that has no effect on the frequency
of CD4+Foxp3+ cells (17) in mice with oxazolone-induced
experimental colitis (16). Intrarectal administration of oxazolone
(6mg in 50% ethanol) was associated with weight loss and the
onset of distal colitis (Figures 4A,B), as previously described
(16). This colitis was associated with significantly higher
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TABLE 2 | Histopathologic score of colons of mice with oxazolone colitis administered the anti-LAP antibody or its isotype control.
Treatment Mouse Total
A B C D E F (A+B+C+D+E+F)
0–3 0–3 0–3 0–3 0–3 0–3 0–15
aLAPAb->OXZ 6mg A distal colonic tract 0 2 0 3 2 2 9
medial colonic tract 0 2 0 3 2 0 7
proximal colonic tract 0 0 0 0 0 0 0
aLAPAb->OXZ 6mg B distal colonic tract 0 2 0 2 2 1 7
medial colonic tract 0 1 0 2 1 1 5
proximal colonic tract 0 0 0 0 0 0 0
aLAPAb->OXZ 6mg C distal colonic tract 0 3 0 3 3 3 12
medial colonic tract 0 2 0 2 3 2 9
proximal colonic tract 0 0 0 0 0 0 0
IsoAb->OXZ 6mg D distal colonic tract 0 3 0 3 3 3 12
medial colonic tract 0 0 0 0 0 0 0
proximal colonic tract 0 0 0 0 0 0 0
IsoAb->OXZ 6mg E distal colonic tract 0 3 0 3 2 2 10
medial colonic tract 0 0 0 0 0 0 0
proximal colonic tract 0 0 0 0 0 0 0
IsoAb->OXZ 6mg F distal colonic tract 0 2 0 3 3 1 9
medial colonic tract 0 0 0 0 0 0 0
proximal colonic tract 0 0 0 0 0 0 0
Mean SE
aLAPAb->OXZ 6mg distal colonic tract 9 1.8
medial colonic tract 7 1.4
proximal colonic tract 0 0.0
IsoAb->OXZ 6mg distal colonic tract 10 1.1
medial colonic tract 0 0.0
proximal colonic tract 0 0.0
Colons were divided into three sections (proximal, medial, and distal), multiple serial sections were done and slides were scored according with 5 criteria from 0 to 3 (A,
hypervascularization; B, presence of mononuclear cells; C, epithelial hyperplasia; D, epithelial damage; E, presence of granulocytes; F, mucosal hemorrhages) to produce a cumulative
histopathologic score (HS) ranging from 0 (no colitis) to 15 (maximal colitis activity).
percentages of LP CD3+CD4+LAP+ cells (Figure 4C) in
uninvolved tissue as compared with both involved tissue andwith
tissue from untreated control mice, and a higher percentage of
CD3+CD4+Foxp3+ cells in involved tissue as compared with
both uninvolved tissue and control untreated mice (Figure 4D),
thus reproducing the observations made in UC patients. In
oxazolone colitis, the significant increased% of CD4+LAP+ cells
in uninvolved vs. involved tissue was confirmed also by confocal
microscopy (Figures 4E,F). After a preliminary validation of the
ability of anti-LAP antibody administration to selectively deplete
LP CD4+LAP+cell without affecting the % of LP CD4+Foxp3+
cells (Supplementary Figure 2), we administered the antibody or
its isotype control in two groups of mice, before the induction of
oxazolone colitis. Administration of anti-LAP antibody had no
effect on weight loss, which was comparable to that observed in
isotype-treated mice (Figure 5A), but was associated with more
extensive colitis (Figures 5B,C and Table 2).
DISCUSSION
The present findings suggest that LP CD3+CD4+LAP+ Tregs
are responsible for limiting the extension of inflammatory
lesions in UC. We observed increases in both the percentage
of CD3+CD4+LAP+ cells and the proportion of IL-10-
expressing CD3+CD4+LAP+ cells associated with a reduction
of IL-17-expressing CD3+CD4+LAP+ cells in uninvolved vs.
involved tissue from UC patients. Previous studies have reported
increases in the numbers of CD3+CD4+LAP+ cells (14) and
CD3+CD4+Foxp3+ cells (24, 25) in involved UC tissue, the
former were found to be functionally impaired in vitro, while
the latter, although functional in vitro, were ineffective in
counteracting inflammation in vivo. Indeed, in the present study,
uninvolved tissue is characterized by a significant increase in the
ratio between IL-10 and IL-17 expressing LAP+ cells suggesting
that the increased % of CD3+CD4+LAP+ cells observed in
uninvolved tissue is predominantly represented by functional
active regulatory cells. This hypothesis is reinforced by the
observations obtained in mice since selective depletion of LAP+
cells in a mouse model of distal colitis was associated with the
extension of inflammatory lesions to the proximal colon. Taken
together, these data strongly suggest that CD3+CD4+LAP+
regulatory cells play a key role in limiting the extension of colonic
inflammatory lesions in UC. CD3+CD4+LAP+ cells (which
express surface TGF-β linked to its latency associated peptide
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FIGURE 5 | Depletion of LAP+ cells is associated with proximal extension of inflammatory lesions in the mouse oxazolone-induced colitis model. (A) Weight changes
in oxazolone-treated mice (6 mg/ethanol 50%) pretreated with either Isotype Ab or anti-LAP Ab. Each point represents the cumulative mean (± SE) weight from 3
separate experiments in which 5 mice per group were studied. (B) Representative macroscopic images of colons of oxazolone-treated mice pretreated with (a)
Isotype Ab or (b) anti-LAP Ab. (C) H&E stained colonic specimens (40× magnification) of distal, medial and proximal colonic portions of oxazolone-treated mice
pretreated with (a) Isotype Ab (a1-a4) or (b) anti-LAP Ab Isotype Ab (b1-b4). HS, histopathologic score (see methods).
[LAP]) have been shown to limit inflammation in the adoptive
transfer mouse model of experimental colitis (28) and are crucial
to ensure protection against murine TNBS colitis, since transfer
of CD4+LAP+ depleted cells with intact CD4+Foxp3+ cells
does not prevent TNBS colitis in recipient mice (29). In mice, the
frequency of CD3+CD4+LAP+ cells is increased in conditions
of increased intestinal permeability and during the homeostatic
response to transient increases in intestinal permeability (29, 30).
Furthermore, the frequency of these cells in the intestinal LP is
increased in human patients with UC but not Crohn’s disease
(14), and their regulatory activity is significantly reduced in
inflamed UC tissue due to an increase in the proportion of
IL-17-expressing LAP+ cells (14). Studies in animal models of
autoimmune diseases have shown that intracellular expression of
IL-10 is linked to the ability of CD4+LAP+ cells to attenuate
disease severity (26, 27). In the present study, we found that
the proportion of CD3+CD8- (CD4) LAP+ cells expressing
intracellular IL-10 was significantly higher in uninvolved vs.
involved tissue from UC patients, suggesting a regulatory role
of these cells, which may limit the extension of inflammatory
lesions. Nasal administration of anti-CD3 in animal models
induces suppressive IL-10-producing T cells (Tr1 cells), almost
75% of which exhibit cell surface expression of LAP (31). The
link between the Tr1 cell subset and the CD3+CD4+LAP+
Foxp3-cells described in the present study remains unknown,
and further studies will be necessary to clarify this relationship.
However, our findings suggest that the suppressive capabilities
of these cells are dependent on LAP expression, since depletion
of LAP+ cells in mice with oxazolone-induced colitis was
associated with proximal extension of colonic inflammatory
lesions. Supporting this view, we previously demonstrated that
blockade of TGF-β activity in oxazolone-induced colitis is
associated with the development of extensive colitis (16).
We found that while the proportion of CD3+CD4+LAP+
cells was increased in uninvolved tissue, the proportion of
CD3+CD4+Foxp3+ cells in the same tissue was comparable
to that seen in controls, suggesting that the requirements
for CD3+CD4+LAP+ cell expansion differ to those for
CD3+CD4+Foxp3+ cell expansion. In mice, in vivo expansion
of CD3+CD4+LAP+ cells is dependent on the presence of IL-
10 and TLR2 (21, 29, 32), and the presence of TGF-β, acting in an
autocrine fashion, is required for LAP expression independently
of Foxp3 expression (22). It is therefore tempting to speculate
that in uninvolved tissue, TGF-β levels facilitate the maintenance
and expansion of CD3+CD4+LAP+ regulatory cells but are
insufficient to induce CD3+CD4+Foxp3+ Tregs.
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It is increasingly apparent that microbiota play an important
role in modulating the intestinal immune system, influencing
different immune-cell subsets and their soluble products. We
previously reported that the expansion of CD3+CD4+LAP+
cells in mice is dependent on the presence of microbiota
(29, 30), and showed that probiotic administration increases
the percentage of LP CD3+CD4+LAP+ cells and protects
mice from TNBS-induced colitis (32). Moreover, we have
demonstrated that probiotic administration in patients with
ileal pouch anal anastomosis for ulcerative colitis is associated
with an increased percentage of CD3+CD4+LAP+ cells in
the pouch LP and a decrease in pouch disease activity index
(13). Taken together, these observations suggest that expansion
of LP CD3+CD4+LAP+ cells may constitute a therapeutic
strategy to limit and possibly prevent colonic inflammation inUC
patients. Microbiota modulation might represent a useful tool to
accomplish this task.
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